Jnana Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 90

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $800M

Jnana Therapeutics General Information

Description

Developer of a drug discovery platform designed to target the solute carrier family of transporters and cell's metabolic gates. The company's platform addresses therapeutic targets across immune metabolism, lysosomal function, and mucosal defense, solute carrier cell transporters provide novel targets for immuno-oncology, inflammatory disorders, and neurological diseases, enabling companies to comprehensively address therapeutic targets across the vast member membrane protein family.

Contact Information

Website
www.jnanatx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • One Design Center Place
  • Suite 19-400
  • Boston, MA 02210
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • One Design Center Place
  • Suite 19-400
  • Boston, MA 02210
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Jnana Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 08-Oct-2024 $800M Completed Pre-Clinical Trials
3. Later Stage VC (Series C1) 15-Nov-2022 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 18-Aug-2021 $50M $100M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 01-Jul-2017 $50M $50M Completed Startup
To view Jnana Therapeutics’s complete valuation and funding history, request access »

Jnana Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-2
Series C-1
Series B
Series A-1 34,500,000 $0.000100 3% $0.5 $0.5 1x $0.5 10.44%
Series A 32,950,000 $0.000100 3% $1 $1 1x $1 9.97%
To view Jnana Therapeutics’s complete cap table history, request access »

Jnana Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to target the solute carrier family of transporters and cell's metabolic
Drug Discovery
Boston, MA
90 As of 2024

Abingdon, United Kingdom
 

Branford, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Jnana Therapeutics Competitors (103)

One of Jnana Therapeutics’s 103 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Azitra Formerly VC-backed Branford, CT
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Virometix Venture Capital-Backed Schlieren, Switzerland
Circle Pharma Venture Capital-Backed South San Francisco, CA
You’re viewing 5 of 103 competitors. Get the full list »

Jnana Therapeutics Patents

Jnana Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025217521-A1 Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist Pending 12-Apr-2024
AU-2025254297-A1 Treating chronic kidney disease with a combination of slc6a19 and sglt2 inhibitors Pending 12-Apr-2024
WO-2025217520-A1 Treating chronic kidney disease with a combination of slc6a19 and sglt2 inhibitors Pending 12-Apr-2024
EP-4761732-A1 Naphthyl-containing piperidine inhibitors of slc6a19 function Pending 17-Aug-2023
WO-2025038949-A1 Naphthyl-containing piperidine inhibitors of slc6a19 function Inactive 17-Aug-2023 A61P3/10
To view Jnana Therapeutics’s complete patent history, request access »

Jnana Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jnana Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
Avalon Ventures Venture Capital Minority
Bain Capital Life Sciences Corporate Venture Capital Minority
Pfizer Ventures Corporate Venture Capital Minority
Polaris Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Jnana Therapeutics FAQs

  • When was Jnana Therapeutics founded?

    Jnana Therapeutics was founded in 2017.

  • Where is Jnana Therapeutics headquartered?

    Jnana Therapeutics is headquartered in Boston, MA.

  • What is the size of Jnana Therapeutics?

    Jnana Therapeutics has 90 total employees.

  • What industry is Jnana Therapeutics in?

    Jnana Therapeutics’s primary industry is Drug Discovery.

  • Is Jnana Therapeutics a private or public company?

    Jnana Therapeutics is a Private company.

  • What is the current valuation of Jnana Therapeutics?

    The current valuation of Jnana Therapeutics is .

  • What is Jnana Therapeutics’s current revenue?

    The current revenue for Jnana Therapeutics is .

  • How much funding has Jnana Therapeutics raised over time?

    Jnana Therapeutics has raised $207M.

  • Who are Jnana Therapeutics’s investors?

    AbbVie Ventures, Avalon Ventures, Bain Capital Life Sciences, Pfizer Ventures, and Polaris Partners are 5 of 7 investors who have invested in Jnana Therapeutics.

  • Who are Jnana Therapeutics’s competitors?

    Adaptimmune Therapeutics, Azitra, CytomX Therapeutics, Virometix, and Circle Pharma are some of the 103 competitors of Jnana Therapeutics.

  • When was Jnana Therapeutics acquired?

    Jnana Therapeutics was acquired on 08-Oct-2024.

  • Who acquired Jnana Therapeutics?

    Jnana Therapeutics was acquired by Otsuka Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process